Treatment Outcomes for Drug-Resistant Tuberculosis Patients on Bedaquiline-Based Regimens in a Mostly Rural South Africa
Authors:
Open Access
- 1 April 2025
- journal article
- research article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 1819-1829
Abstract
Background: Tuberculosis (TB) has maintained its position as a leading global health crisis. The situation of DR-TB is exacerbated by the emergence of drug resistance, particularly rifampicin resistant TB (RR-TB), multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB). Bedaquiline (BDQ) has now become part of all standard drug-resistant regimens globally. However, emerging BDQ resistance is a growing worry, especially in areas with high rates of TB and HIV. This study aimed to compare BDQ-based regimens to non-BDQ-based treatments over a four-year period (2016– 2019) to retrospectively examine the treatment outcomes of DR-TB patients in Limpopo Province, South Africa. Methodology: Using patient data from the Limpopo Province Electronic Drug-resistant TB Register (EDR) Web, a retrospective study was carried out. The study comprised 1,665 DR-TB patients; 880 (52.8%) of them were given BDQ-based regimens, whereas 785 (47.2%) were given non-BDQ regimens. Treatment success, death, loss to follow-up, and six-month sputum culture conversion were important outcomes. Kaplan–Meier survival analysis was used to assess the data for mortality, chi-square tests were used for categorical comparisons, and logistic regression models were used to find treatment success predictors. Results: The results of the analysis showed that the BDQ cohort had far better treatment success rates 560/785 (71%) than the non-BDQ cohort 549/880 (62%). Patients receiving BDQ had a reduced overall death rate and quicker sputum culture conversion at six months 608/785 (77.5%) vs 597/880 (67.8%). Kaplan–Meier curve survival analysis revealed a statistically significant survival benefit. Age, HIV status, and BDQ use were found to be significant determinants of treatment effectiveness using logistic regression. Conclusion: In South Africa’s mostly rural areas, BDQ-containing regimens proved to be more effective in enhancing treatment outcomes and lowering mortality rates for DR-TB patients. But to keep TB treatment regimens successful, comprehensive drug susceptibility testing and ongoing surveillance are required considering the growing concern over BDQ resistance.Keywords
This publication has 40 references indexed in Scilit:
- Trends & treatment outcomes of multidrug-resistant tuberculosis in Delhi, India (2009-2014)Indian Journal of Medical Research, 2020
- Treatment of Highly Drug-Resistant Pulmonary TuberculosisNew England Journal of Medicine, 2020
- Whole genome sequencing for drug-resistant tuberculosis management in South Africa: What gaps would this address and what are the challenges to implementation?Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019
- Laboratory evaluation of four HIV/syphilis rapid diagnostic testsBMC Infectious Diseases, 2019
- Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort studyThe Lancet Respiratory Medicine, 2018
- Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort StudyClinical Infectious Diseases, 2018
- Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort StudyEBioMedicine, 2018
- Bedaquiline Resistance: Its Emergence, Mechanism, and PreventionClinical Infectious Diseases, 2017
- Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug ResistanceClinical Infectious Diseases, 2015
- Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational studyClinical Microbiology and Infection, 2012